Tandem Diabetes Revenue vs. Shares Owned By Insiders
| TNDM Stock | USD 30.63 0.59 1.89% |
Total Revenue | First Reported 2011-12-31 | Previous Quarter 221.9 M | Current Value 363.3 M | Quarterly Volatility 87 M |
For Tandem Diabetes profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tandem Diabetes to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tandem Diabetes Care utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tandem Diabetes's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tandem Diabetes Care over time as well as its relative position and ranking within its peers.
Tandem |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tandem Diabetes Care Shares Owned By Insiders vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Tandem Diabetes's current stock value. Our valuation model uses many indicators to compare Tandem Diabetes value to that of its competitors to determine the firm's financial worth. Tandem Diabetes Care is rated below average in revenue category among its peers. It also is rated below average in shares owned by insiders category among its peers . The ratio of Revenue to Shares Owned By Insiders for Tandem Diabetes Care is about 983,839,474 . At this time, Tandem Diabetes' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tandem Diabetes by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tandem Revenue vs. Competition
Tandem Diabetes Care is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 119.77 Billion. Tandem Diabetes maintains roughly 747.72 Million in revenue contributing less than 1% to equities under Health Care industry.
Tandem Shares Owned By Insiders vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Tandem Diabetes |
| = | 747.72 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Tandem Diabetes |
| = | 0.76 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Tandem Shares Owned By Insiders Comparison
Tandem Diabetes is currently under evaluation in shares owned by insiders category among its peers.
Tandem Diabetes Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Tandem Diabetes, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tandem Diabetes will eventually generate negative long term returns. The profitability progress is the general direction of Tandem Diabetes' change in net profit over the period of time. It can combine multiple indicators of Tandem Diabetes, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.4 M | 1.4 M | |
| Operating Income | -233.2 M | -221.6 M | |
| Income Before Tax | -220.3 M | -209.2 M | |
| Total Other Income Expense Net | 13 M | 13.6 M | |
| Net Loss | -222.6 M | -211.5 M | |
| Income Tax Expense | 2.4 M | 2.5 M | |
| Net Loss | -222.6 M | -211.5 M | |
| Non Operating Income Net Other | -3.6 K | -3.8 K | |
| Net Loss | -108.8 M | -114.2 M | |
| Interest Income | 22.9 M | 24 M | |
| Net Interest Income | 13 M | 13.6 M | |
| Change To Netincome | 140 M | 147 M |
Tandem Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Tandem Diabetes. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tandem Diabetes position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tandem Diabetes' important profitability drivers and their relationship over time.
Use Tandem Diabetes in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tandem Diabetes position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tandem Diabetes will appreciate offsetting losses from the drop in the long position's value.Tandem Diabetes Pair Trading
Tandem Diabetes Care Pair Trading Analysis
The ability to find closely correlated positions to Tandem Diabetes could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tandem Diabetes when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tandem Diabetes - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tandem Diabetes Care to buy it.
The correlation of Tandem Diabetes is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tandem Diabetes moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tandem Diabetes Care moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tandem Diabetes can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Tandem Diabetes position
In addition to having Tandem Diabetes in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
To fully project Tandem Diabetes' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Tandem Diabetes Care at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Tandem Diabetes' income statement, its balance sheet, and the statement of cash flows.